The Claim
In obese adults, treatment with tirzepatide results in a 14.7% mean reduction in body weight over two years, compared to a 10.8% mean reduction with semaglutide, and a higher proportion of individuals achieve at least 15% weight loss (42.6% vs. 21.6%).
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Among obese adults, those treated with tirzepatide lost an average of 14.7% of their body weight over two years, while those treated with semaglutide lost an average of 10.8%. More people on tirzepatide lost at least 15% of their body weight compared to those on semaglutide.
See the scientific wording
In obese adults treated with tirzepatide or semaglutide, tirzepatide is associated with a 14.7% mean reduction in body weight over two years compared to 10.8% with semaglutide, with a higher proportion achieving ≥15% weight loss (42.6% vs. 21.6%), suggesting greater efficacy in real-world clinical settings.
Tirzepatide activates two receptors in the brain that control hunger, making people feel full faster and for longer, while semaglutide activates only one. This stronger signal reduces food intake more, leading to greater weight loss.
What the research says
1 studyStudy: Weight-loss dynamics with tirzepatide versus semaglutide
This study found that people taking tirzepatide lost more weight on average than those taking semaglutide, and twice as many hit the 15% weight loss goal — exactly what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.